Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Simon Tarsh | Interim Chief Financial Officer | 306k | -- | 1961 |
| Dr. Francois Binette M.Sc., Ph.D. | COO and Executive VP for Research & Development | 402.5k | -- | 1964 |
| Mr. David H. Weinstein | CEO & Director | -- | -- | 1960 |
| Dr. Serhat Gümrükcü | Co-Founder & Inventor | -- | -- | -- |
| Mr. Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations | -- | -- | -- |
Renovaro Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 25
Description
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Corporate Governance
Upcoming Events
February 12, 2025 at 9:00 PM UTC - February 17, 2025 at 9:00 PM UTC
Renovaro Inc. Earnings Date
Recent Events
November 4, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission